Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AIM ImmunoTech (AIM) Free Cash Flow (2018 - 2025)

Historic Free Cash Flow for ImmunoTech (AIM) over the last 11 years, with Q3 2025 value amounting to -$5.1 million.

  • ImmunoTech's Free Cash Flow fell 6331.19% to -$5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.9 million, marking a year-over-year increase of 3752.84%. This contributed to the annual value of -$14.9 million for FY2024, which is 2991.02% up from last year.
  • Latest data reveals that ImmunoTech reported Free Cash Flow of -$5.1 million as of Q3 2025, which was down 6331.19% from -$1.5 million recorded in Q2 2025.
  • Over the past 5 years, ImmunoTech's Free Cash Flow peaked at -$1.5 million during Q2 2025, and registered a low of -$9.8 million during Q4 2023.
  • Over the past 3 years, ImmunoTech's median Free Cash Flow value was -$3.7 million (recorded in 2023), while the average stood at -$4.1 million.
  • In the last 5 years, ImmunoTech's Free Cash Flow skyrocketed by 5946.92% in 2024 and then crashed by 6331.19% in 2025.
  • Over the past 3 years, ImmunoTech's Free Cash Flow (Quarter) stood at -$9.8 million in 2023, then skyrocketed by 59.47% to -$4.0 million in 2024, then fell by 28.42% to -$5.1 million in 2025.
  • Its Free Cash Flow stands at -$5.1 million for Q3 2025, versus -$1.5 million for Q2 2025 and -$2.4 million for Q1 2025.